YMAB Message Board Post 10011804 | Y-mAbs Therapeutics Inc.
home / stock / ymab / ymab message board
Alfredoescano
(investorshub)
Posted on: Dec/24/2020 02:16:10
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160449147
8-K: License agreement with SciClone Pharmaceuticals International.
News, Short Squeeze, Breakout and More Instantly...
-
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
-
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...